Shortly after Sanofi CEO Paul Hudson joined the company in 2019, he laid out an ambition to invest as much as necessary to turn the Regeneron-partnered antibody drug Dupixent into a megablockbuster. Two years later, Sanofi is well on its way.
This is the time to double down : Top Vertex executives defend research plan as pressure builds biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.